Yilmaz Tabel, Turgut Piskin, Bulent Unal

Çocuk Hastalara Yaptığımız Böbrek Nakilleri ile İlgili İlk Deneyimlerimiz ve Sonuçlarımız

Amaç: Hem çocuk hem de erişkin böbrek yetmezliği hastaları için en iyi tedavi seçeneği yaşam süresini ve kalitesini de artıran böbrek naklidir. Kasım 2010 ile Mayıs 2014 tarihleri arasında toplam 117 hastaya böbrek nakli yaptık bunların 13’ü çocuk hastalardı. Çocuk hastalara yaptığımız böbrek nakilleri ile ilgili ilk deneyimlerimizi ve sonuçlarımızı burada sunmayı amaçladık. Materyal ve Metot: En bloc ve dual böbrek nakli yaptığımız bir olgumuz bu çalışmanın dışında bırakıldı. Geriye kalan 12 hasta ve donörlerinin kayıtları geriye doğru toplanarak incelendi. Bulgular: Hastalarımızın 7’sine kadavradan, 5’ine canlı donörlerinden nakil yaptık. Canlı donörden nakil yaptığımız alıcıların ortalama takip süreleri 31.8 ay(dağılım; 1-42 ay), kadaverik donörden nakil yaptığımız alıcıların ise16.8 aydı (dağılım; 2-28 ay). Takip süresince greft sağkalım oranı %100’dü. Teknik nedenlerden, altta yatan hastalıkların tekrar etmesi, infeksiyon ya da rejeksiyon nedeni ile organ kaybetmedik. Sonuç: Çocuk yaş grubundaki kronik böbrek yetmezliği olan hastlara kadaverik ya da canlı donörden olabildikçe erken böbrek nakili yapılmalıdır. Çocuklara; hem kadavradan hemde canlıdan nakiller nakil merkezi yeni kurulmuş olsada güvenli bir şekilde yapılabilinir.

Our Initial Experiences and Outcomes of Pediatric Kidney Transplantations

Objectives: Kidney transplantation is the best treatment method associated with improvedquality of life and better survival for both adult and pediatric patients with end stage renaldisease. We have performed a total of 117 kidney transplantations from living or deceaseddonors between November 2010 and May 2014. Thirteen of these were pediatric kidneytransplantations. Here, we present our initial experiences and outcomes of these pediatrickidney transplantations.Materials and Methods: One of the pediatric recipients who underwent en bloc and dualkidney transplantation from a deceased donor was excluded from this study. This recipientwas a 40-month-old patient whose donor was an eleven-month-infant. Her allograft kidneyswere explanted because of vascular thrombosis on the first postoperative day. We collectedand retrospectively analyzed the data of the other twelve pediatric transplantation recipientsand their donors. Seven of these kidney transplantations were from deceased donors and fivefrom living donors. All recipients and the five living donors underwent a thorough examinationand their clinical history was studied with in detail.Results: Deceased to living donor ratio was 7:5, respectively. The mean follow up period was31.8 (1-42) months from living donors group and 16.8 (2-28) months from deceased donorsgroup, respectively. Graft survival was 100% during this period. No kidney was lost fromrejection, technical causes, infection or recurrent diseases. The living donors are also still alivewithout any problems.Conclusion: For pediatric end stage renal disease patients, kidney transplantation should bedone from deceased or living donors as soon as possible.

PDF

___

1. Sinha A, Hari P, Guleria S, Gulati A, Dinda AK, Mehra NK, et al. Outcome of pediatric renal transplantation in nort India. Pediatr Transplant 2010;14(7):836-43.
2. Patel UD. Outcomes after pediatric kidney transplantation improving: how can we do even better? Pediatrics 2014;133(4):734-5
3. Ishitani M, Isaacs R, Norwood V, Nock S, Lobo P. Predictors of graft survival in pediatric livingrelated kidney transplant recipients. Transplantation 2000;70(2):288-92.
4. Schurman SJ, McEnery PT. Factors influencing shortterm and long-term pediatric renal transplant survival. J Pediatr 1997;130(3):455-62.
5. Garcia CD, Bittencourt VB, Tumelero A, Antonello JS, Moura DM, Vitola SP, et al. 300 pediatric renal transplantations: A single-center experience. Transplant Proc 2006;38(10):3454-5.
6. Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum on the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation 2005;79:53-66.
7. Danovitch GH: In Veale JL, Singer JS, Gritsch HA (eds): Handbook of Kidney Transplantation, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2009;181-97.
8. Weber LT. Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol 2015;30(2):253- 65.
9. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9(8):1511-20.
10. Ginevri F, De Santis R, Comoli P, Pastorino N, Rossi C, Botti G,et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003;75(8):1266-70.
11. Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004;4(12):2109-17.
12. Fraser N. Lyon PC, Williams AR, Christian MT, Shenoy MU. Native nephrectomy in pediatric transplantation— less is more! J Pediatr Urol 2013;9(1):84-9.
13. Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal transplantation: a special report of the North AmericanPediatric Renal Transplant Cooperative Study. Transplantation 1997;63(9):1263-7.
14. McEnery PT, Stablein DM, Arbus G, Tejani A. Renal transplantation in children. A report of the North American Pediatric Renal TransplantCooperative Study. N Engl J Med 1992;326(26):1727-32.